160 related articles for article (PubMed ID: 28336956)
1. Preclinical development of a humanized neutralizing antibody targeting HGF.
Kim H; Hong SH; Kim JY; Kim IC; Park YW; Lee SJ; Song SW; Kim JJ; Park G; Kim TM; Kim YH; Park JB; Chung J; Kim IH
Exp Mol Med; 2017 Mar; 49(3):e309. PubMed ID: 28336956
[TBL] [Abstract][Full Text] [Related]
2. YYB-101, a Humanized Antihepatocyte Growth Factor Monoclonal Antibody, Inhibits Ovarian Cancer Cell Motility and Proliferation.
Kim HJ; Heo K
Anticancer Res; 2021 Feb; 41(2):671-678. PubMed ID: 33517271
[TBL] [Abstract][Full Text] [Related]
3. Progress of antibody-based inhibitors of the HGF-cMET axis in cancer therapy.
Kim KH; Kim H
Exp Mol Med; 2017 Mar; 49(3):e307. PubMed ID: 28336955
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of tumor growth in a mouse xenograft model by the humanized anti-HGF monoclonal antibody YYB-101 produced in a large-scale CHO cell culture.
Song SW; Lee SJ; Kim CY; Song JK; Jung EJ; Choi YB; Min SW; Oh JW
J Microbiol Biotechnol; 2013 Sep; 23(9):1327-38. PubMed ID: 23851271
[TBL] [Abstract][Full Text] [Related]
5. A novel rabbit anti-hepatocyte growth factor monoclonal neutralizing antibody inhibits tumor growth in prostate cancer cells and mouse xenografts.
Yu Y; Chen Y; Ding G; Wang M; Wu H; Xu L; Rui X; Zhang Z
Biochem Biophys Res Commun; 2015 Aug; 464(1):154-60. PubMed ID: 26093299
[TBL] [Abstract][Full Text] [Related]
6. Identification of genomic and molecular traits that present therapeutic vulnerability to HGF-targeted therapy in glioblastoma.
Sa JK; Kim SH; Lee JK; Cho HJ; Shin YJ; Shin H; Koo H; Kim D; Lee M; Kang W; Hong SH; Kim JY; Park YW; Song SW; Lee SJ; Joo KM; Nam DH
Neuro Oncol; 2019 Feb; 21(2):222-233. PubMed ID: 29939324
[TBL] [Abstract][Full Text] [Related]
7. A novel antagonist anti-cMet antibody with antitumor activities targeting both ligand-dependent and ligand-independent c-Met receptors.
Gonzalez A; Broussas M; Beau-Larvor C; Haeuw JF; Boute N; Robert A; Champion T; Beck A; Bailly C; Corvaïa N; Goetsch L
Int J Cancer; 2016 Oct; 139(8):1851-63. PubMed ID: 27144973
[TBL] [Abstract][Full Text] [Related]
8. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors.
Burgess T; Coxon A; Meyer S; Sun J; Rex K; Tsuruda T; Chen Q; Ho SY; Li L; Kaufman S; McDorman K; Cattley RC; Sun J; Elliott G; Zhang K; Feng X; Jia XC; Green L; Radinsky R; Kendall R
Cancer Res; 2006 Feb; 66(3):1721-9. PubMed ID: 16452232
[TBL] [Abstract][Full Text] [Related]
9. Humanized Anti-hepatocyte Growth Factor Monoclonal Antibody (YYB-101) Inhibits Ovarian Cancer Progression.
Kim HJ; Lee S; Oh YS; Chang HK; Kim YS; Hong SH; Kim JY; Park YW; Lee SJ; Song SW; Kim JJ; Heo K
Front Oncol; 2019; 9():571. PubMed ID: 31355133
[TBL] [Abstract][Full Text] [Related]
10. LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth.
Liu L; Zeng W; Wortinger MA; Yan SB; Cornwell P; Peek VL; Stephens JR; Tetreault JW; Xia J; Manro JR; Credille KM; Ballard DW; Brown-Augsburger P; Wacheck V; Chow CK; Huang L; Wang Y; Denning I; Davies J; Tang Y; Vaillancourt P; Lu J
Clin Cancer Res; 2014 Dec; 20(23):6059-70. PubMed ID: 25231402
[TBL] [Abstract][Full Text] [Related]
11. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models.
Cao B; Su Y; Oskarsson M; Zhao P; Kort EJ; Fisher RJ; Wang LM; Vande Woude GF
Proc Natl Acad Sci U S A; 2001 Jun; 98(13):7443-8. PubMed ID: 11416216
[TBL] [Abstract][Full Text] [Related]
12. GD2-directed CAR-T cells in combination with HGF-targeted neutralizing antibody (AMG102) prevent primary tumor growth and metastasis in Ewing sarcoma.
Charan M; Dravid P; Cam M; Audino A; Gross AC; Arnold MA; Roberts RD; Cripe TP; Pertsemlidis A; Houghton PJ; Cam H
Int J Cancer; 2020 Jun; 146(11):3184-3195. PubMed ID: 31621900
[TBL] [Abstract][Full Text] [Related]
13. Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models.
Piao Y; Park SY; Henry V; Smith BD; Tiao N; Flynn DL; de Groot JF
Neuro Oncol; 2016 Sep; 18(9):1230-41. PubMed ID: 26965451
[TBL] [Abstract][Full Text] [Related]
14. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts.
Kim KJ; Wang L; Su YC; Gillespie GY; Salhotra A; Lal B; Laterra J
Clin Cancer Res; 2006 Feb; 12(4):1292-8. PubMed ID: 16489086
[TBL] [Abstract][Full Text] [Related]
15. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo.
Martens T; Schmidt NO; Eckerich C; Fillbrandt R; Merchant M; Schwall R; Westphal M; Lamszus K
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6144-52. PubMed ID: 17062691
[TBL] [Abstract][Full Text] [Related]
16. Targeting the MET oncogene by concomitant inhibition of receptor and ligand via an antibody-"decoy" strategy.
Basilico C; Modica C; Maione F; Vigna E; Comoglio PM
Int J Cancer; 2018 Oct; 143(7):1774-1785. PubMed ID: 29693242
[TBL] [Abstract][Full Text] [Related]
17. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice.
Kuba K; Matsumoto K; Date K; Shimura H; Tanaka M; Nakamura T
Cancer Res; 2000 Dec; 60(23):6737-43. PubMed ID: 11118060
[TBL] [Abstract][Full Text] [Related]
18. Nonclinical evaluation of the serum pharmacodynamic biomarkers HGF and shed MET following dosing with the anti-MET monovalent monoclonal antibody onartuzumab.
Mai E; Zheng Z; Chen Y; Peng J; Severin C; Filvaroff E; Romero M; Mallet W; Kaur S; Gelzleichter T; Nijem I; Merchant M; Young JC
Mol Cancer Ther; 2014 Feb; 13(2):540-52. PubMed ID: 24258345
[TBL] [Abstract][Full Text] [Related]
19. Biochemical and pharmacological characterization of human c-Met neutralizing monoclonal antibody CE-355621.
Michaud NR; Jani JP; Hillerman S; Tsaparikos KE; Barbacci-Tobin EG; Knauth E; Putz H; Campbell M; Karam GA; Chrunyk B; Gebhard DF; Green LL; Xu JJ; Dunn MC; Coskran TM; Lapointe JM; Cohen BD; Coleman KG; Bedian V; Vincent P; Kajiji S; Steyn SJ; Borzillo GV; Los G
MAbs; 2012; 4(6):710-23. PubMed ID: 23007574
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity, pharmacokinetics, tumor-homing effect, and hepatotoxicity of a species cross-reactive c-Met antibody.
Park H; Kim D; Son E; Shin S; Sa JK; Kim SH; Yoon Y; Nam DH
Biochem Biophys Res Commun; 2017 Dec; 494(1-2):409-415. PubMed ID: 28917835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]